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Abstract 
 
Combinations of therapeutic agents could synergistically enhance the response of lung 
cancer cells. Co-delivery systems capable of transporting chemotherapeutics with different 
physicochemical properties and with the simultaneous release of drugs remain elusive. 
Here, we assess the ability of nanoparticles of 30-nm diameter obtained from the self-
assembly of hyaluronan-based copolymer targeting CD44 receptors to encapsulate both 
gefitinib and vorinostat for effective combinational lung cancer treatment. Drug loading 
was performed by nanoprecipitation. Drug release experiments showed a slow release of 
both drugs after 5 days. Using two- and three-dimensional lung adenocarcinoma cell 
cultures, we observed that the nanoparticles were mostly found at the periphery of the 
CD44-expressing spheroids. These drug-loaded nanoparticles were as cytotoxic as free 
drugs in the two- and three-dimensional systems and toxicity was due to apoptosis 
induction. In mouse models, intravenous injection of hyaluronan-based nanoparticles 
showed a selective delivery to subcutaneous CD44-overexpressing tumors, despite a 
significant liver capture. In addition, the systemic toxicity of the free drugs was reduced by 
their co-delivery using the nanoparticles. Finally, intrapulmonary administration of drug-
loaded nanoparticles, to avoid a possible hepatic toxicity due to their accumulation in the 
liver, showed a stronger inhibition of orthotopic lung tumor growth compared to free 
drugs. In conclusion, hyaluronan-based nanoparticles provide active targeting partially 
mediated by CD44, less-toxic drug release and improved antitumor efficiency. 
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Introduction 
 
Lung cancer is the leading cause of cancer-related adult deaths worldwide.[1] Improved 
understanding of the molecular changes that drive tumor progression has revolutionized 
the clinical management of non-small cell lung cancer (NSCLC). In lung cancers with 
epidermal growth factor receptor (EGFR)-activating mutations, anti-EGFR therapies, 
including gefitinib, erlotinib, and afatinib, have been shown to improve progression-free 
survival and were approved as first-line options.[2, 3] For patients without targetable 
oncogenic driver mutations representing 60% of NSCLC cases, first-line treatment with 
standard chemotherapy agents (i.e. cisplatin and permetrexed or docetaxel) is still the 
standard of care.[3] The chemotherapy agents, docetaxel and pemetrexed, and the EGFR-
TKIs erlotinib and gefitinib are approved for the second- and third-line treatment of 
advanced NSCLC, or as maintenance therapy. The role of EGFR-TKIs as second- and 
third-line therapy for patients with EGFR wild-type tumors remains controversial, and 
highlighted the existence of intrinsic resistance mechanisms.[4] Despite continuous 
improvements in cancer treatments, the prognosis is poor, and the development of new 
approaches is urgently needed. Combinations of targeted agents might be exploited to 
inhibit more than one pathway and could be significantly more effective in achieving 
tumor regression than single therapeutic agents. We and others contributed to establish that 
combination treatment with histone deacetylase inhibitors and EGFR-TKIs synergistically 
leads to more effective treatments.[5-9] 
 
Major efforts have been made to generate nanovectors that will deliver the therapeutic 
molecules specifically to the tumor sites, protect them from degradation, allow better 
spatiotemporal release and thus limit their side effects.[10] Co-delivery of therapeutic 
agents exhibiting synergy into a single nanocarrier is difficult owing to the different 
physicochemical properties of each agent. Polymeric micellar nanostructures, and 
especially polymeric vesicles also referred as polymersomes, are powerful tools in terms of 
efficacy, specificity, and controlled release of both hydrophilic and hydrophobic 
molecules.[11-13] In this context, we previously developed glycopolypeptide-based 
nanocarriers[14-16] that combined the natural polysaccharide hyaluronan, known for its 
relative affinity toward CD44 receptors that are up-regulated on some cancer cells and 
involved in tumor growth, progression and metastasis, and poly(J-benzyl-L-glutamate) 
(PBLG), a biodegradable polypeptide characterized by an ordered secondary structure (α-
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helix).[17, 18] These nanoparticles (NP) showed active targeting of CD44-overexpressing 
lung tumor cells in vitro and in vivo,[19] suggesting that they could be used as a targeted 
drug-delivery system. 
 
In the present study, we report the synthesis, loading and efficacy of hyaluronan-based NP 
for the delivery of a combination of vorinostat, a histone deacetylase inhibitor, with 
gefitinib, an EGFR-TKI. These drug-loaded nanoparticles (DLNP) were tested in NSCLC 
cells expressing different levels of CD44, cultured in two-dimensions (2D) and three-
dimensions (3D spheroids). In addition, their toxicity and therapeutic effects were 
evaluated in vivo using an orthotopic tumor model of NSCLC in nude mice. 
 
Methods 
 
Materials 
Hyaluronan (5000 g/mol) was from Lifecore Biomedical; near infrared dye Dy-700 was 
from Life Technologies. Vorinostat (SAHA, MK0683), and gefitinib (ZD1839) were 
obtained from Selleckchem (Munich, Germany). γ-benzyl-L-glutamate N-
carboxyanhydride (NCA-BLG) was purchased from Isochem (France) and use as received. 
 
Copolymer synthesis and characterization 
Synthesis of hyaluronan-b-poly(γ-benzyl-L-glutamate) copolymer by 1,3 Huisgen 
cycloaddition: As previously described and well characterized by Jeannot et al.,[19] the 
synthetic strategy used was based on the coupling reaction between azide-end 
functionalized poly(γ-benzyl-L-glutamate) (PBLG) having a degree of polymerization of 
60 and alkyne-end functionalized hyaluronan of 5000 g/mol using a Huisgen 1,3-dipolar 
cycloaddition click chemistry reaction in DMSO at 50°C. The copolymer was purified by 
successive dialysis and ultrafiltration steps against water (yield=60%). The purified 
copolymer was fully characterized by H1 NMR, FTIR and SEC in DMSO as shown by 
Jeannot et al.[19] 
 
Copolymer labeling with fluorescent Dy-700 dye: Hya-b-PBLG was labeled as previously 
described by Jeannot et al.,[19] and used to obtain labeled nanoparticles. Briefly, the 
diblock copolymer (1 eq.) was dissolved in anhydrous DMSO (50 mg/mL) and 
triethylamine (1 eq. per acid function) was added, followed by the addition of 0.1 
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equivalent of Dy-700, and stirred overnight at room temperature. The reaction mixture was 
dialyzed against ultrapure water for one day and freeze-dried, protected from light. A 
labeling efficiency of 10 mol% was measured in DMSO by UV spectroscopy (720 nm) 
using ε = 90,000 M-1.cm-1 according to the manufacturer’s instructions. 
 
Nanoparticle preparation 
NP were formulated by a solvent displacement technique (nanoprecipitation), as previously 
described.[19] To obtain labeled fluorescent nanoparticles, an equimolar mixture of Hya-b-
PBLG-Dy-700 and Hya-b-PBLG copolymer was used to obtain 5 mol% of labeled 
copolymer. A fast nanoprecipitation technique was used to obtain small NP near to 30 nm. 
Hya-b-PBLG was dissolved in DMSO (10 mg.mL-1) and rapidly mixed with a tenfold 
volume of phosphate buffer at 50°C using a micropipette. The organic solvent was then 
removed by dialysis (MWCO 25 kDa) against water for 24 h, with the medium changed 
every 4 h. The NP were then characterized by static and dynamic light scattering (SLS and 
DLS) and by transmission electron microscopy (TEM).[19] 
 
Nanoparticle drug loading 
DLNP were obtained by a fast nanoprecipitation process. Solutions of Hya-b-PBLG, 
gefitinib and vorinostat were prepared in DMSO at a concentration of 20 mg.mL-1 for the 
copolymer and 12 mg.mL-1 for drugs. Then, 0.2 mL of copolymer solution and 0.1 mL of 
each drug solution were mixed together and added to an excess (1.6 mL) of phosphate 
buffer at 50°C using a micropipette. Non-encapsulated drug was then removed from the 
nanoprecipitation medium by dialysis (MWCO 25 kDa) against buffer phosphate for 14 h. 
The final NP were filtered through 0.22-μm cellulose filter to remove insoluble drug 
aggregates. 
The drug loading content in the NP was determined from the final solution (2 mL) with a 
copolymer concentration of 2 mg.mL-1. The filtered NP were freeze-dried and dissolved in 
2 mL of EtOH. The mixture was stirred by vortex and sonication for 30 min and stirred for 
another 30 min to ensure drug extraction. Finally, the sample was centrifuged (9160 g, 30 
min) and the supernatant analyzed by UV spectroscopy (UV-530 spectrophotometer, 
Jasco) at O = 330 nm for gefitinib and O = 240 nm for vorinostat. Quantification of 
gefitinib and vorinostat was performed from the calibration curve of these drugs in ethanol 
made in the 96-well plate (0.2 mL/well). Each experiment was carried out in triplicate, and 
average values were calculated. The drug loading content in the NP is defined herein as the 
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ratio of the mass of drugs in the NP to the total mass (polymer + drug). The entrapment 
efficiency was also derived from the ratio of the mass of drugs in particles to the initial 
mass of drug used for the nanoprecipitation step. For biological tests, samples were stored 
freeze-dried after the addition of 10% mannitol to ensure complete redispersion. The 
particles were reconstituted at 2 mg/mL in PBS buffer and filtered on 0.45-µm cellulose 
membranes before use to remove any traces of polymer aggregates. 
 
In vitro drug release study 
The in vitro drug release of gefitinib and vorinostat NP formulations was performed with 
the as-prepared particle suspension (2 mL) after a dialysis of 14 h against phosphate buffer 
and a filtration through 0.22-μm cellulose filter to remove non-encapsulated drug. Release 
experiments were conducted by dialysis (MWCO 25kDa) under sink conditions. The 
dialysis bag was kept in a beaker containing 50 mL of pH 7.4 phosphate buffer containing 
2% ethanol. The beaker was placed on a magnetic stirrer, and the temperature of the 
assembly was maintained at 37°C throughout the experiment. After defined incubation 
times, samples (1 mL) were removed and replaced with equal amounts of pH 7.4 
phosphate buffer containing 2% ethanol, followed by freeze-drying. The concentration of 
the released gefitinib and vorinostat contained in the medium was determined by UV 
analysis after drug extraction, as previously described. Each experiment was carried out in 
triplicate, and average values were calculated. 
 
Cell culture 
The human H322, H358 and A549 NSCLC cell lines were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). 
 
2D cell culture: Cells were maintained in RPMI 1640 (Gibco, Cergy Pontoise, France) 
supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere with 5% 
CO2. We routinely carried out morphology checks on all cell lines, and we only passaged 
the cell lines for 3 months. All cell lines were routinely tested for the presence of 
mycoplasma (MycoAlert® Mycoplasma Detection Kit, Lonza, France). 
 
3D cell culture: Spheroids were generated by plating 4000 A549 or 5000 H358 cells/well 
into 96-well round bottom Ultra Low Attachment (ULA) spheroid microplates (Corning, 
Tewksbury, USA). These plates stimulate the spontaneous formation of a single spheroid 
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of cells within 48 hours. Spheroid culture was performed in RPMI 1640 supplemented with 
10% FBS in a humidified atmosphere with 5% CO2. Spheroid formation and growth was 
assessed by microscopic examination using an inverted microscope and by imaging 
spheroids at each time point. The volume of each spheroid was measured by MetaMorph 
software (Molecular Devices, Wokingham, United Kingdom).  
 
In vitro cytotoxicity study 
Cell proliferation assays were conducted in 96-well culture plates. 2D-cultured cells and 
spheroids were cultured for 24 and 72 hours, respectively, prior to treatment in a dose-
dependent manner with gefitinib and/or vorinostat in medium containing 10% FBS, or 
were washed in PBS and treated with NP in serum-free medium. The viability was 
quantified using CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) 
in monolayer cell culture or using CellTiter-Glo® 3D Cell Viability Assay (Promega) in 
spheroids. Growth inhibition was expressed as the percentage of surviving drug-treated 
cells compared to untreated control cells. The drug concentrations required to inhibit cell 
growth by 50% (IC50) were determined by interpolation from the dose-response curves.  
 
Apoptosis assays 
Active caspase-3 cleavage in 2D-cultured cells was detected by flow cytometry using a 
phycoerythrin-conjugated monoclonal active caspase-3 antibody kit (BD Pharmingen, Le 
Pont de Claix, France), following the manufacturer’s instructions. The analysis was 
performed on a BD-Accuri C6 flow cytometer with CFlow-plus software (BD 
Biosciences). Active caspase-3 was also detected in frozen spheroid sections by 
immunofluorescence (see “immunofluorescence and microscopy studies” below). 
 
Immunofluorescence and microscopy studies 
Immunofluorescence studies were performed on 2D-cultured cells after washing and 
fixation in 4% paraformaldehyde for 20 min, or on spheroids after washing and fixation 
overnight at 4°C in 2% paraformaldehyde. Spheroids were embedded in OCT (Optimal 
cutting temperature), cut into 7-µm sections, mounted on SuperFrost UltraPlus slides 
(Menzel-Gläser) and rehydrated in PBS-glycine for 20 min. After blocking in 10% goat 
serum, primary antibodies (Ki67 (Abcam), active caspase-3 (Cell Signaling Technology), 
or CD44 (Santa Cruz) antibodies) were incubated overnight at 4°C on monolayer cells or 
spheroid sections, then washed in PBST (0.2% Tween 20 in PBS). Goat anti-mouse Alexa 
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Fluor 488 conjugated secondary antibodies (Dako) were then incubated for 1 hour. 
Hoechst counterstained cell nuclei. Fluorescence microscopy was carried out using an 
LSM710 NLO confocal microscope (Carl Zeiss, Jena, Germany). 
Spheroids were washed before Dy-700-labeled nanoparticle incubation for 24 hours at 
37°C and 5% CO2. Spheroids were then harvested, washed, fixed and frozen in OCT for 
embedding. Spectral images were acquired on 7-µm sections with an LSM710 NLO (Carl 
Zeiss, Jena, Germany) laser scanning confocal microscope. The excitation laser 
wavelength was 633 nm, and spectral images were acquired from 645 to 723 nm in 9.7 nm 
steps with a 40X/1.2W Korr C-Apochromat objective lens. Spectra for autofluorescence 
and Dy-700 were acquired in the same conditions and used for linear spectral unmixing of 
samples with the software Zen 2010 (Carl Zeiss, Jena, Germany). 
 
In vivo studies 
All animal experiments were performed in agreement with the European Economic 
Community guidelines and the “Principles of Laboratory Animal Care” (NIH publication 
N 86-23 revised 1985). Animal experiment studies were approved through institutional 
guidelines and by the European Community for the use of experimental animals 
(authorization to experiment 00393.02).  
 
NP administration in healthy mice: Anesthetized (isoflurane/air 4% for induction and 1.5% 
thereafter) healthy female NMRI nude mice (Janvier, Le Genest, Saint Isle, France) were 
daily injected intravenously via the tail vein with 200 µL of vehicle (1X PBS, control), Dy-
700 labeled NP (2 mg/mL), gefitinib and vorinostat-loaded NP (DLNP 2 mg/mL), or 
gefitinib and vorinostat at the same concentration as encapsulated in NP (72 µg/mL 
gefitinib and 5.2 µg/mL vorinostat) for 11 days. Mice were observed and weighed daily, 
and blood was collected by cardiac puncture at the end of the experiment for further 
analysis. Biochemistry analysis of blood samples was performed using a Dimension Vista® 
System automate following manufacturer’s instructions. 
 
NP biodistribution in vivo: Female NMRI nude mice (6–8 weeks old, Janvier, Le Genest-
Saint Isle, France) were injected subcutaneously in the flank with 20×106 H358 or H322 
cells, or 10×106 A549 cells in PBS. Tumor size was measured twice a week using a caliper, 
and the tumor volume was calculated as follows: length×(width)2×0.4. When subcutaneous 
tumors of ~250 mm3 in size were detected, anesthetized mice (isoflurane/air 4% for 
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induction and 1.5% thereafter) were injected intravenously via the tail vein with 200 µL of 
Dy-700 labeled NP (8 mg/mL). 2D-fluorescent images and black and white pictures were 
acquired after administration using a back-thinned CCD camera at -80°C (ORCAII-BT-
512 G, Hamamatsu, Massy, France) that was ﬁtted with a long-pass RG 700 ﬁlter, as 
previously described.[19] After 24 h, mice were sacrificed, and some organs and tumors 
were collected for ex vivo imaging. Semiquantitative data were obtained using the Wasabi® 
software (Hamamastsu, Massy, France) by drawing regions of interest (ROIs) on the 
different organs and were expressed as the number of Relative Light Units per pixel per 
unit of exposure time and relative to the fluorescence signal in the skin. 
 
Antitumor efficacy of DLNP in mice with orthotopic lung tumor: Luciferase-modified 
human A549 NSCLC cells (A549-Luc cells) were suspended in medium with 10 mM 
EDTA and 4 mg/mL Matrigel (BD Biosciences) at 5.106 cells/50 µL. Six-week-old female 
BALB/c nude mice (Janvier, Le Genest, Saint Isle, France) were anesthetized 
(isoflurane/air 4% for induction and 1.5% thereafter), and the cells were inoculated in the 
lungs via the airways as previously described.[19] Tumor growth was followed by in vivo 
bioluminescence imaging (IVIS Kinetic, Perkin-Elmer) 10 min after the intraperitoneal 
injection of 150 mg/kg of Luciferin (Promega, Charbonnières, France), as previously 
described.[19] 
The A549-Luc cells inoculated nude mice were randomly divided into 3 groups of 10 
mice: a control group and DLNP and drug-alone treated groups. Intrapulmonary 
administration of 50 µL of gefitinib and vorinostat-loaded nanoparticles (2 mg/mL in 1X 
PBS) or gefitinib and vorinostat combination at the same concentration as encapsulated in 
nanoparticles (72 µg/mL gefitinib and 5.2 µg/mL vorinostat in 1X PBS/0.2% DMSO) was 
performed using a nebulizing IA-1C Microspayer (Penn-Centur, Inc., PA, USA) connected 
to a FMJ-250-high-pressure syringe (Penn-Centur, Inc.) in anesthetized mice 
(isoflurane/air 4% for induction and 1.5% thereafter). The tip of the microsprayer was 
introduced into the trachea of the animals using a dedicated laryngoscope. DLNP and 
drugs alone were nebulized 2 days after inoculation of cells in the lungs, to let animals 
recover from tumor cells implantation, and then once a week. Mice were observed and 
weighed three times a week. Tumor growth was followed by in vivo bioluminescence 
imaging. Mice without any thoracic bioluminescence signal at day 8, or with only tracheal 
bioluminescence, were excluded from the in vivo bioluminescence imaging analysis. 
Tumor burden was estimated as the mean of the in vivo bioluminescence signal. Tumor 
 10 
doubling time was calculated according the formula: 34 x Ln(2) / (Ln(Bioluminescence at 
day 42) / (Bioluminescence at day 8). After 7 weeks, mice were sacrificed, and blood 
samples were collected by cardiac puncture for biochemistry analysis (Charles River 
Laboratory, MA, USA). Lungs were collected for immunohistochemistry analyses. 
 
Immunohistochemistry 
Lungs were frozen and sections of a 7-μm thickness were fixed with 4% 
paraformaldehyde, stained with hematoxylin and eosin (HE) or incubated overnight at 4°C 
with antibodies. Immunohistochemical staining of Ki67 and cleaved caspase-3 was 
performed as previously described.[20] Lung sections were observed under a Zeiss 
AxioImager M2 microscope. 
 
Statistical analyses 
Statistical comparisons were made using a Mann-Whitney U-test or analysis of variance 
test. Two-sided p values ≤0.05 were considered statistically significant. All analyses were 
performed using the Statview software (Abacus Concept, Berkeley, CA, USA). 
 
Results and Discussion 
 
Preparation and characterization of copolymer nanoparticles 
The copolymer synthesis and self-assembly were adapted from a previously reported 
publication.[19] Briefly, chemically modified hydrophilic hyaluronan (5,000 g.mol-1) was 
covalently linked to a hydrophobic polypeptide, the poly(y-benzyl-L-glutamate), (PBLG, 
DP 60) using the 1,3 Huisgen cycloaddition. Hya-b-PBLG60 was then modified by a 
coupling reaction using the primary amine of PBLG and a dye probe (Dy-700) bearing a 
maleimide function to obtain a fluorescent copolymer (Figure 1A).[19] Block copolymer 
NP were prepared through a fast nanoprecipitation approach where the polymer solution in 
DMSO at 50°C is quickly added to a large excess of PBS buffer pH 7.4, which is a non-
solvent of the block copolymer. Under such conditions, block copolymer chains experience 
a phenomenon of so-called supersaturation, where the actual polymer concentration in the 
medium becomes much higher than the polymer solubility in same conditions. As a 
consequence, block copolymer chains undergo a rapid desolvation, leading to the 
formation of small nuclei that can grow through association with copolymer chains that 
remain in solution or by particle aggregation.[21] Block copolymer NP grow until a dense 
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overlapping hyaluronan brush layer is formed on the surface of the particle, which hinders 
further chain exchange or interparticle fusion.[22] A key parameter of the process is the 
mixing time of the organic solution with the aqueous phase, which determines the local 
supersaturation value and subsequent conditions of nanoprecipitation. In general, the lower 
the mixing time, the higher the nucleation rate and the smaller the particles.[23] Here, 
monodispersed spherical nanoparticles of 30 nm were obtained by fast nanoprecipitation. 
They were fully characterized by static and dynamic light scattering (SLS and DLS), 
transmission electron microscopy (TEM) as reported previously (Figure 1B).[19] This 
small particle size was related to both the fast mixing protocol, which guarantees uniform 
supersaturation in the solution and therefore homogeneous conditions for 
nanoprecipitation, and to the presence of hyaluronan blocks, which act as efficient 
stabilizers through an electrosteric mechanism. The weight-average molecular weight of 
NP determined by SLS was 1.3 106 g/mol. This corresponds to approximately 75 
copolymer chains per nanoparticle. TEM analysis evidenced the presence of NP clusters, 
which result from the increase in particle concentration during the drying step. These 
clusters are forming weak structures that are only observed after solvent removal since any 
insoluble aggregates could be detected by DLS in solution. By looking closely at the TEM 
picture, it can be seen that the particles are spherical with a typical size close to 30 nm, 
consistent with the diameters determined by DLS. 
 
Drug loading and release 
Drug loading was performed by the same nanoprecipitation method used for empty block 
copolymer particles but in the presence of gefitinib and vorinostat. While the drug loading 
(ratio of the mass of drugs in NP to the total mass) of gefitinib was quite satisfactory (7.3 
%), this was not the case with vorinostat, where a loading content of 0.35% was obtained. 
On the other hand entrapment efficiencies (mass of encapsulated drug) of 24.5% and 1.2% 
were found respectively for gefitinib and vorinostat. To achieve a high drug loading 
content, the precipitation times of the copolymer and drugs needed to match to favor the 
simultaneous co-precipitation of components.[24] The water-solubility of vorinostat 
(0.0716 mg/mL) was higher than that of gefitinib (0.027 mg/mL).[25] Its precipitation was 
thus slower than that of the copolymer and gefitinib, and a large proportion of vorinostat 
molecules were not incorporated in the NP. The molecules rather formed aggregates that 
were removed during the filtration step. Particle size and dispersity of DLNP were similar 
to those observed for empty ones (Figure 1C). 
 12 
DLNP were lyophilized to improve their long-term stability. Before freeze-drying, 10% 
(w/v) of mannitol was added to the medium to protect DLNP during freeze-drying and 
minimize particle aggregation after redispersion in PBS. Mannitol should not modify the 
size and the drug content of DLNP[26]. Drug-release experiments were performed in sink 
conditions at 37°C in PBS pH 7.4 containing 2% of ethanol to improve drug solubility in 
the released medium. Figure 1D evidences poor release of both vorinostat and gefitinib 
after 5 days. A blank experiment performed in same conditions showed that free drugs are 
fully released thus evidencing that the dialysis membrane is neither limiting the release nor 
adsorbing drugs (Supplementary material S1). However, a certain amount of loaded drugs 
can be lost during the first dialysis of 14 h that was performed right after the particle 
Figure 1: Characterization of NP and drug release.  
A: Chemical structure of the amphiphilic hyaluronan-b-PBLG copolymer and the Dy-700 end-labeled copolymer. B: 
Characterization of block copolymer NP obtained through a fast nanoprecipitation process. From left to right: intensity-
weighted size distribution and polydispersity index (PDI) of nanoparticles obtained by DLS analysis at a detection angle 
of 90°; TEM analysis of dried nanoparticles deposited on a carbon:formwar film coated grid and stained with 1.5% 
uranyl acetate solution. C: Intensity-weighted size distribution and polydispersity index (PDI) of DLNP after 
purification obtained by DLS analysis at 90°C. D: Drug release profile at 37°C in PBS pH 7.4 from block copolymer NP 
encapsulating a combination of gefitinib and vorinostat. 
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preparation to remove the excess of non-encapsulated drugs (see Methods). In addition, 
some aggregation of drug loaded particles were observed during dialysis after 24 h, thus 
limiting the diffusion of the drug (Supplementary material S1). Other reasons behind the 
poor release are the relatively high hydrophobicity of both drugs, as characterized by log P 
values of 1.44 (vorinostat) and 3.2 (gefitinib)[25], the possible crystalline state of the drugs 
within particles or their strong interaction with the PBLG blocks. Whatever the physical 
origin behind the poor release, which remains to be elucidated, this result emphasizes that 
block copolymer NP would need to be degraded in the local tumor environment to release 
their payload. Because typical in vitro drug release experiments do not mimic in vivo 
conditions[27-30], further experiments in presence of serum or cathepsin degrading PBLG 
blocks are needed to study the release of the drugs. 
 
Analysis of nanoparticle uptake by fluorescence microscopy in spheroids 
Before assessing NP uptake in spheroids, which mimic solid tumors with appropriate cell-
cell interactions as well as gradients of nutrients and oxygen,[31] we first analyzed the 
expression level of CD44 using confocal microscopy in H358 and A549 NSCLC cells 
cultured in monolayer or in spheroids. As previously observed by flow cytometry,[19] CD44 
expression levels were higher in A549 than in H358 cells in monolayer cell culture 
(Supplementary material S2). CD44 expression was also strongly detected in A549 cells 
cultured in spheroids, both at the periphery and within the spheroids. As expected, CD44 was 
very low in H358 spheroids.  
We previously reported the stronger CD44-dependent binding and internalization of these 
NP in NSCLC A549 compared to H358 cells in 2D cell culture.[19] Here, we assessed Dy-
700-labeled NP uptake in A549 and H358 spheroids by microscopy using spectral imaging 
coupled with image analysis and linear unmixing using the model spectra of the free dye and 
the surrounding autofluorescence, thus determining the specific location of NP on sections. 
NP were mostly found at the periphery of the A549 spheroids, with an intracytoplasmic 
punctate labeling of the peripheral cells (Figure 2 and Supplementary material S2). A faint 
punctate labeling was also observed in H358 spheroids, but only with stronger laser 
intensities (Supplementary material S2). When examined by confocal microscopy, Dy-700 
NP partially colocalized with CD44 immunostaining in A549 spheroids (Figure 2). 
Quantification showed that 61% of Dy-700 NP positive cells expressed CD44 (83/135 Dy-
700 NP positive cells). A549 cells do not express the receptor for hyaluronan-mediated 
motility (RHAMM), another receptor of hyaluronan,[32] and according to the level of 
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expression of CD44 in spheroids and to our previous data,[19] NP uptake appears at least 
partially correlated to CD44 receptor expression. Further experiments are needed to confirm 
NP uptake in multicellular tumor spheroids, which will reflect also the tumor 
microenvironment. 
Cytotoxicity of drugs in monolayer cell culture and in spheroids 
We first compared the ability of increasing concentrations of gefitinib or vorinostat to 
inhibit the growth of H358 and A549 cells. As previously observed,[9] the sensitivity to 
gefitinib dramatically varied when these cells were cultured in 2D or 3D (Supplementary 
material S3). The IC50 of gefitinib increased from 15 µmol/L in A549 cells in 2D to 25 
µmol/L in A549 spheroids (Supplementary materials S3 and S4). In contrast, the IC50 of 
gefitinib was strongly decreased when H358 cells were in spheroids compared to 
monolayers (0.2 and 1.3 µmol/L, respectively). These results are in agreement with the 
literature[33] and highlight that the toxicity of drugs significantly varies when measured in 
spheroids or in monolayer cell cultures. One explanation should be that the signaling 
pathways of the drugs are different in 2D and 3D cultures. Accordingly, we observed 
reduced amounts of phosphorylated- and total-EGFR levels in A549 spheroids, whereas 
Figure 2: Uptake of NP by 
A549 spheroids.  
A549 spheroid sections 
show membrane CD44 
expression (in green), the 
specific binding of Dy-700-
labeled NP (Dy-700 NP, in 
purple) after 24 hours, and 
their colocalization (merge). 
Nuclei are stained with 
Hoechst (in blue). Arrows 
show CD44 and NP 
colocalization in the same 
cells. Scale bars: 20 µm. 
Figure 2 
CD44 Dy700-NP 
Hoechst merge 
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the level of expression of EGFR, but not phosphorylated-EGFR, decreased in H358 
spheroids (Supplementary material S5). This maintenance of EGFR activity, despite the 
decreased level of the EGFR protein, could explain the higher sensitivity of H358 
spheroids to gefitinib. The IC50 of vorinostat was in the same range in A549 cells in 2D 
and 3D cultures (1.5-2 and 2.5-3 µmol/L, respectively; Supplementary materials S3 and 
S4) and did not change in H358 cells (3.5 µmol/L), suggesting that not all drugs have 
different responses in 2D and 3D culture systems.  
 
Cytotoxicity of DLNP in monolayer NSCLC cell culture 
We previously evidenced that gefitinib and vorinostat synergized in H358 and A549 cells.[7, 
9] To investigate whether the simultaneous delivery of drugs by NP promotes efficient 
therapeutic efficacy, the cytotoxicity and apoptosis induction with NP loaded with gefitinib 
and vorinostat were assessed. Two different NP concentrations were compared to those of 
free drugs used. The concentrations were chosen based on the IC50 of gefitinib or 
vorinostat in 2D cell culture (Supplementary material S4). Empty NP inhibited the viability 
of A549 cells overtime as compared to control cells (Figure 3A). This could be explained 
by the strong binding and internalization of empty NP in these NSCLC cells, as previously 
observed.[19] A549 cells treated with DLNP exhibited a significantly decreased viability 
over time compared to control cells or cells treated with empty NP (Figure 3A). This effect 
was dose-dependent. At low concentrations, DLNP were as efficient as free drugs in A549 
cells. Conversely, at high concentrations, DLNP were less efficient than free gefitinib and 
vorinostat. The impact of DLNP on H358 cell viability was approximately the same as 
those of free drugs, except at 12.5 µg/mL at 72 hours, where it was weaker (Supplementary 
material S6).  
In agreement with the cell proliferation assays, DLNP showed dose-dependent apoptosis 
induction in A549 cells (Figure 3B). The co-treatment with free gefitinib and vorinostat 
was slightly more effective than DLNP in inducing caspase-3 cleavage. This was also 
observed in H358 cells at low concentration, whereas DLNP were more toxic at high 
concentration (Supplementary material S6). Empty NP did not show significant apoptosis 
induction in both cell lines (Figure 3B and Supplementary material S6). Taken together, 
these findings are consistent with the drug sensitivity observed in spheroids 
(Supplementary materials S3 and S4) and indicate that the inhibition of cell viability by 
DLNP is associated with an induction of apoptosis, at least in the same range as free 
gefitinib and vorinostat combination in NSCLC cells cultured in 2D.  
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Cytotoxicity of DLNP in NSCLC spheroids 
In the presence of DLNP, the volumes of A549 spheroids were reduced, but the 
encapsulated drugs were less efficient than the free drug combination (Figure 4A). The 
viability of A549 cells in spheroids was affected in a dose-dependent manner after 72 
hours of treatment, and the free drugs were more toxic only at higher concentration (Figure 
4B). Encapsulated drugs were as efficient as free ones on the volume and cell viability of 
the H358 spheroids (Supplementary material S7).  
These data were further confirmed by immunofluorescence analyses on spheroids. Nuclear 
protein Ki67 immunostaining did not show significant differences in the number of 
proliferating cells in A549 spheroids, whatever the treatment (Figure 4C and 4D). 
Consistently, active caspase-3 labeling in A549 spheroids showed that both free drugs or 
DLNP induced similar levels of apoptosis (Figure 4E and 4F). In contrast, H358 spheroids 
treated with the free drugs showed a surprising modest increase in Ki67 immunostaining 
compared to control or DLNP treatments (Supplementary material S7). A stronger 
activation of caspase-3 after DLNP treatment than after free drugs treatment was observed  
(supplementary material S7).  
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Figure 3: Cell proliferation and apoptosis assays 
in NSCLC cells treated with DLNP. 
A549 cells in 2D monolayer cell culture were treated 
for 72 hours in absence of serum with vehicle 
(control), empty NP (Dy-700 NP), 
gefitinib/vorinostat-loaded NP (DLNP) or a 
combination of gefitinib and vorinostat at the same 
concentration as encapsulated in NP: 185 µg/mL NP 
encapsulated gefitinib 15µmol/L/vorinostat 
1.8µmol/L; 50 µg/mL NP encapsulated gefitinib 
4µmol/L/vorinostat 0.5µmol/L. Cell viability (A) 
was determined at 24, 48 and 72 hours. Results are 
expressed as the mean ± SD (representative 
experiment among 3). *p<0.05 compared to control; 
#p>0.05 as indicated. Caspase-3 activation (B) was 
detected by flow cytometry after 72 hours of 
treatment. Results are expressed as the mean ± SD 
(n≥2). *p<0.05 compared to control; #p>0.05 as 
indicated; ns not significant.  
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In vivo biodistribution of the NP 
The tumor targeting capacity of these NP was assessed in human NSCLC subcutaneous 
tumor models. Equal quantities of Dy-700-labeled NP were injected intravenously in mice 
with A549, H358, or H322 subcutaneous tumors, which have different levels of expression 
of CD44.[19] After 24 hours, and as previously observed, the strongest fluorescence 
signals were measured in the liver (Figure 5A), which highlighted the hepatic elimination 
of the NP, as expected due to their size and opsonisation.[19, 34-37] These NP have a 
negative surface charge, which is also promoting recognition by the reticulo-endothelial 
system and uptake by the liver.[34, 38] Five kilodalton hyaluronan fragments were used for 
NP synthesis. As can be seen in supplementary material S8, these fragments had a limited 
liver retention compared to 35 kDa fluorescent hyaluronan fragments, in agreement with 
the known hepatic capture of 10-100 kDa hyaluronan fragments. This capture is due to the 
overexpresion of the hyaluronan receptor for endocytosis (HARE) in the liver.[39, 40] 
Nonetheless, a small proportion of NP reached the tumors, and accumulated more strongly 
in the CD44-overexpressing A549 tumors compared to H358 (low expression of CD44) 
and H322 (CD44 negative tumor) tumors (Figure 5B), suggesting that active CD44 receptor 
targeting could play a role in NP retention.[19] Liver uptake is a common important 
problem observed with most NP, including targeted ones.[41] Our biodistribution 
observations highlight the need to reduce the hepatic capture of the NP, for instance by 
pre-injecting free hyaluronan to occupy HARE receptors (supplemetary material S8).[34, 
40] In addition, the active targeting of CD44-expressing tumors must be enhanced, 
possibly by modulating the hyaluronan size of the NP.[42, 43] 
Figure 4: Proliferation and apoptosis assays in NSCLC spheroids treated with DLNP. 
A549 spheroids were treated for 72 hours in absence of serum with vehicle (control), DLNP or a combination of gefitinib 
and vorinostat at the same concentration as encapsulated in NP: 185 µg/mL NP encapsulated gefitinib 15µmol/L/vorinostat 
1.8µmol/L; 50 µg/mL NP encapsulated gefitinib 4µmol/L/vorinostat 0.5µmol/L. A: The growth of spheroids is followed 
by microscopy at 24, 48 and 72 hours, and the volume is calculated using MetaMorph software. Data represent the mean ± 
SD of 20 spheroids in 2 independent experiments. Representative images of A549 spheroids in each condition are 
presented. B: Cell viability was determined at 72 hours on spheroids. Data represent the mean ± SD of 20 spheroids in 2 
independent experiments. C-F: A549 spheroids were treated in absence of serum (control), gefitinib/vorinostat-loaded NP 
(DLNP) or a combination of gefitinib and vorinostat at the same concentration as encapsulated in NP: 50 µg/mL 
nanoparticles encapsulated gefitinib 4µmol/L/vorinostat 0.5µmol/L. Representative images of Ki67 (C) or cleaved-caspase 
3 (E) staining detected through immunostaining on frozen spheroid sections are shown. In blue: Hoechst staining of the 
nuclei. Scale bar: 50 µm. Ki67 (D) or cleaved-caspase 3 (F) positive cells were quantified. Three slides randomly selected 
per spheroid were analyzed, counting all cells per slide. Histograms represent the mean ± SD of 3 spheroids. 
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Figure 5: Biodistribution of NP and drugs after intravenous 
injection in vivo. 
In vivo biodistribution of Dy-700-labelled NP in mice with A549, 
H358, or H322 subcutaneous tumors was studied. Fluorescence 
images were performed on isolated organs 24 hours after 
intraveneous injection of NP. A: Regions of interest (ROI) are 
defined on the extracted organs to semi-quantify the amount of 
photons detected per pixel after a 500 ms exposure. The results 
are expressed as the mean ± SD in A549 tumor-bearing mice 
(n=4), H358 tumor-bearing mice (n=2), and H322 tumor-bearing 
mice (n=4). The strongest fluorescence signals were measured in 
the liver and spleen. Examples of organs extracted from A549, 
H358, and H322 tumor-bearing mouse treated with Dy700-NP is 
presented. B: ROI are defined on the extracted tumors to semi-
quantify the amount of photons detected per pixel after a 500 ms 
exposure after intravenous injection of NP. The results are 
expressed as the tumor/skin fluorescence ration ± SD in A549 
tumor-bearing mice (n=4), H358 tumor-bearing mice (n=2), and 
H322 tumor-bearing mice (n=4). The NP fluorescent signal was 2 
times higher in A549 tumors than in H322 or H358 tumors. 
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In vivo toxicity of the NP 
Daily repeated intravenous injection of healthy mice with vehicle, Dy-700-NP, DLNP (2 
mg/mL) or free gefitinib and vorinostat combination at the same concentration as 
encapsulated in NP (gefitinib 72 µg/mL and vorinostat 5.2 µg/mL) were well tolerated 
after 11 days. No significant weight loss was observed in the mice (figure 6A). However, a 
cutaneous rash was observed in mice treated with free drugs compared to NP-treated mice 
(figure 6B), as well as a decrease in aspartate aminotransferase (Table 1). This suggested 
that the NP prevented the recurrent cutaneous adverse events of gefitinib.[44] In contrast, a 
small increase in aspartate aminotransferase was observed in the blood of mice treated with 
NP, which could be an indicator of liver injury, but this was not correlated with change in 
other indicators of liver disease, such as alanine aminotransferase, alkaline phosphatase, or 
total proteins. In addition, macroscopic analyses of the organs of NP-treated mice did not 
show evidence of damage (data not shown). This suggested that DLNP did not impair liver 
function despite their strong hepatic accumulation.  
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Figure 6: Toxicity of NP and drugs 
after intravenous injection in vivo. 
Healthy mice were treated daily by 
intravenous injection of vehicle 
(control), Dy-700-NP (2 mg/mL), 
gefitinib/vorinostat-loaded nanoparticles 
(DLNP 2 mg/mL) or a combination of 
gefitinib and vorinostat at the same 
concentration as encapsulated in NP 
(gefitinib 72 µg/mL and vorinostat 5.2 
µg/mL). A: Mice were weighed each 
day. n=2-3 mice per condition. B: 
Gefitinib and vorinostat combination 
induced cutaneous rash. 
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We did not observe other significant changes in electrolytes, creatinine (alteration of 
kidney filtration function), or lipase (marker of pancreatitis) dosages. Taken together, our 
results show that drug encapsulation decreased their side effects. 
 
 
Antitumoral activity of DLNP in an orthotopic model of NSCLC 
Although no toxicity was observed after systemic injection, hepatic accumulation of NP 
prompted us to evaluate the antitumor activity of DLNP through another way of 
administration. Intrapulmonary administration of NP is expected to avoid hepatic 
accumulation. We established a CD44-positive A549 orthotopic lung tumor model. 
Intrapulmonary nebulization of Dy-700-labelled NP showed a very strong signal in the 
lungs, but not in the orthotopic lung tumors.[19] This fluorescent signal remained stable 
for several weeks (Supplementary material S9) without showing adverse effects. Despite 
the absence of NP accumulation in lung tumors, this suggested that these NP could serve as 
a reservoir of drugs and release them slowly in the vicinity of the tumors during a long 
period of time. As soon as the A549 cells were inoculated into the lungs, the mice were 
randomly divided into three groups: one control group and 2 groups nebulized with DLNP 
(2 mg/mL) or free gefitinib and vorinostat combination at the same concentration as in 
DLNP (gefitinib 72 µg/mL and vorinostat 5.2 µg/mL). Nebulization was performed using a 
microsprayer 2 days after tumor implantation and repeated weekly.  
Table 1: Serum biochemical values of healthy mice after NP or drugs administered by IV 
injection 
Serum biochemistry control Dy700-NP DLNP gefitinib + vorinostat 
reference 
values 
(range) 
Cl (mmol/L) 115.0 ± 2.1 112.3 ± 2.1 114.0 ± 0.8 115.4 ± 1.1 109-124 
K (mmol/L) 4.5 ± 1.5 4.8 ± 0.3 4.2 ± 0.1 3.5 ± 0.1 4-9 
Na (mmol/L) 149.9 ± 1.3 152.2 ± 2.5 153.3 ± 0.02 149.3 ± 0.6 147-167 
Ca (mmol/L) 2.4 ± 0.1 2.2 ± 0.03 2.4 ± 0.1 2.4 ± 0.1 2.25-3 
Creatinine (µmol/L) 14.1 ± 1.4 <12.5 <12.5 13.9 ± 1.1 5-60 
aspartate aminotransferase (U/L) 176.3 ± 193.8 226 ± 55.2 240.5 ± 10.6 66 ± 9.9 69-191 
alanine aminotransferase (U/L) 47.5 ± 26 24.9 ± 5.2 43.3 ± 0.8 33.8 ± 6.1 26-120 
total proteins (g/L) 48.6 ± 2.3 45.0 ± 0.1 50.0 ± 5.8 50.6 ± 1.9 47-55 
alkaline phosphatase (U/L) 110.3 ±33.3 57.0 ± 1.4 45.5 ± 2.2 144 ± 9.9 44-118 
Lipase (U/L) 117.0 ± 8.5 160.5 ± 14.8 168 ± 14.1 114.5 ± 14.8  
Healthy mice were treated daily by intravenous injection of 1X PBS (control), Dy700-NP (2 mg/mL), 
gefitinib/vorinostat-loaded nanoparticles (DLNP 2 mg/mL) or a combination of gefitinib and vorinostat at the same 
concentration as encapsulated in NP (gefitinib 72 µg/mL and vorinostat 5.2 µg/mL). After 11 days, blood was 
collected and analyzed using Dimension Vista® System and according to manufacturer’s instructions. Data 
represented the mean ± S.D. of 2-3 mice per condition. 
 22  
5.104  
1.106 C
on
tr
ol
 
G
ef
iti
ni
b 
+ 
vo
rin
os
ta
t 
D
LN
P 
D8 D15 D22 D29 D36 D42 
Figure 7 
A 
B 
C D E 
0,00E+00 
1,00E+07 
2,00E+07 
3,00E+07 
4,00E+07 
5,00E+07 
0 5 10 15 20 25 30 35 40 
Th
or
ac
ic
 b
io
lu
m
in
es
ce
nc
e 
 
(p
ho
to
ns
/s
ec
) 
Days 
Control 
Loaded-NP 
gefitinib + vorinostat 
estimation of gefitinib + vorinostat 1,00E+08 
5,00E+08 
9,00E+08 
# 
DLNP 
0 
25 
50 
75 
100 
125 
150 
Co
ntr
ol 
ge
fiti
nib
 + 
vo
rin
os
tat
 
Lo
ad
ed
-N
P 
Tu
m
or
 b
ur
de
n 
(%
 o
f c
on
tr
ol
) 
-52% 
-65% 
ge
fiti
nib
 + 
vo
rin
os
tat
 
DL
Day 8 
0 
25 
50 
75 
100 
125 
150 
Co
ntr
ol 
ge
fiti
nib
 + 
vo
rin
os
tat
 
Lo
ad
ed
-N
P 
Tu
m
or
 b
ur
de
n 
(%
 o
f c
on
tr
ol
) 
ge
fiti
nib
 + 
vo
rin
os
tat
 
-44% 
-72% 
DL
NP
 
Day 15 
0 
25 
50 
75 
100 
125 
150 
Co
ntr
ol 
ge
fiti
nib
 + 
vo
rin
os
tat
 
Lo
ad
ed
-N
P 
Tu
m
or
 b
ur
de
n 
(%
 o
f c
on
tr
ol
) 
-31% 
-82% 
ge
fiti
nib
 + 
vo
rin
os
tat
 
DL
NP
 
Day 42 
Figure 7: Effects of DLNP after nebulization in A549 orthotopic lung tumors. 
Mice were inoculated with A549-Luc cells and randomized into 3 groups of 10 mice. Gefitinib/vorinostat-loaded NP (DLNP 2 
mg/mL) or a combination of free gefitinib and vorinostat (gefitinib + vorinostat) at the same concentration as encapsulated in NP 
(gefitinib 72 µg/mL and vorinostat 5.2 µg/mL) were administered intrapulmonary in the lungs once a week. Thoracic 
bioluminescence imaging was performed once a week. A: Overtime bioluminescence images of A549-Luc tumors (one 
representative mouse per goup). B: DLNP inhibited the growth of orthotopic A549 lung tumors. Arrows shows treatment 
nebulization. Mice without signal or with bioluminescence only in the trachea have been excluded. Bars, SEM; control, n=6 mice; 
DLNP, n=8 mice; gefitinib + vorinostat, n=4 mice. Numbers indicate the percentage of lung tumor-bearing mice in each group. # 
This thoracic bioluminescent point has been estimated (dotted line) because of the failure of imaging in one mice. C-E: Tumor 
burden was measured at day 8 (C), day 15 (D), and at the end of the experiment (day 42, E) and shown as a percentage of the control 
group. Numbers indicate the percentage of tumor growth inhibition compared to control group. 
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As shown in figure 7A and 7B, bioluminescence imaging of tumor growth indicated that 
the DLNP-treated group showed the slowest tumor growth. Both DLNP and free drug-
treated groups exhibited similar early inhibition of thoracic bioluminescence with 65% and 
52% decrease, respectively, compared to control group at day 8 (Figure 7C). The inhibition 
of tumor growth was even greater at day 15, especially for the DLNP-treated group (figure 
7D). At the end of the experiment, the DLNP-treated group showed 82% decreased tumor 
growth compared to control (Figure 7E). Based on this longitudinal follow-up, the 
doubling time of tumor cell population was calculated and showed that tumor growth was 
slowed only in the DLNP-treated group compared to the control group, with a tumor cell 
population doubling time increased by 71%, but not in the free gefitinib and vorinostat-
treated group (Table 2). Interestingly, the percentage of mice with lung tumors at the end 
of the experiment was reduced in the free drug-treated group compared to control or DLNP 
groups (Table 2). This strongly suggested that nebulized DLNP restrained tumor growth 
over time, whereas free drugs directly inhibited the establishment of tumors but not their 
progression. Nebulization of NP or of therapeutic antibodies has already been successfully 
reported for lung cancer treatment.[45-48] Here, we showed that even if the bronchial 
obstruction due to the presence of tumor should prevent the nebulized DLNP from 
penetrating the tumor,[19] they accumulated over time nearby the tumor and enhanced the 
amount of drugs in tumor microenvironment, thus inhibiting the tumor growth. 
 
Intrapulmonary administration of treatments was well tolerated, and no significant weight 
loss was observed in the mice (Supplementary material S10). We did not observe any 
significant change in serum biochemical values, except a decrease in triglycerides and 
creatinine dosages in free drug-treated mice (Supplementary material S10). We did not 
observe any lung damage on histological sections (Supplementary material S11), but 
pulmonary toxicity should be formally assessed to confirm the safety of nebulized NP.[49] 
Table 2: Doubling time of tumor cell population and percentage of tumor-bearing mice after 
DLNP or free drug nebulization in mice with A549 orthotopic lung tumors. 
  Doubling time of tumor cell population (days) 
Lung tumor-bearing mice 
(%) 
Control 17.1 ± 2.8 70 
DLNP 29.2 ± 5.5 80 
Gefitinib + vorinostat 13.3 ± 3.8 44 
The tumor cell population doubling time of was calculated as described in the methods section based on the 
longitudinal bioluminescence follow-up of mice with A549-Luc cells and nebulized with DLNP or gefitinib and 
vorinostat combination. The percentage of lung tumor-bearing mice in each group were determined at day 42 
among the mice inoculated with A549-Luc cells (n=10 per group). 
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To explore the mechanism underlying the tumor growth inhibition, proliferation and 
apoptosis assays were performed on lung sections (Supplementary material S11). No 
significant difference between the treatments was observed in apoptosis induction in tumor 
cells. In contrast, Ki67 immunostaining showed that the DLNP significantly decreased cell 
proliferation by approximately 30% in A549 tumors compared to the control or free drug-
treatment groups. This indicated that DLNP enhanced the antitumor activity of drug 
combination by reducing the proliferation of tumor cells.[7, 9]  
 
Conclusions 
 
In conclusion, we have developed 30 nm large NP obtained from the self-assembly of 
hyaluronan-based copolymers for the simultaneous delivery of drugs with different 
physicochemical properties. Hyaluronan-based NP are capable of co-loading both 
hydrophobic and hydrophilic chemotherapeutics and provide both active targeting partially 
mediated by CD44 and protection from undesired drug release during circulation. DLNP 
triggered enhanced apoptosis among cancer cells in vitro in monolayer cell culture and in 
spheroids and conferred better antitumor effects in vivo compared to free drug combination 
after intrapulmonary administration. A weekly administration of the DLNP accounted for a 
slow and controlled release of the drugs, which was sufficient to strongly inhibit tumor 
growth and was well tolerated. In contrast, free drugs prevented nesting of tumors since 
fewer mice had a lung tumor, probably by killing tumor cells thanks to a peak of high drug 
concentration during their administration. Because they may diffuse too quickly into lung 
tissues following nebulization, free drugs failed to control the tumor growth. The sustained 
slow drug release with DLNP seems to be more efficient to inhibit the tumor progression. 
Further trials will be needed to optimize the concentrations of drugs combination, as well 
as the ratio of drugs loaded into the DLNP in order to obtain the best therapeutic efficacy. 
This novel hyaluronan-based drug delivery system may hold promise for efficient tumor 
therapy and opens an avenue for exploring the design of more sophisticated delivery 
systems with higher loading capacities and minimum side effects. 
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Figure legends 
 
Figure 1: Characterization of NP and drug release. 
A: Chemical structure of the amphiphilic hyaluronan-b-PBLG copolymer and the Dy-700 
end-labeled copolymer. B: Characterization of block copolymer NP obtained through a fast 
nanoprecipitation process. From left to right: intensity-weighted size distribution and 
polydispersity index (PDI) of nanoparticles obtained by DLS analysis at a detection angle 
of 90°; TEM analysis of dried nanoparticles deposited on a carbon:formwar film coated 
grid and stained with 1.5% uranyl acetate solution. C: Intensity-weighted size distribution 
and polydispersity index (PDI) of DLNP after purification obtained by DLS analysis at 
90°C. D: Drug release profile at 37°C in PBS pH 7.4 from block copolymer NP 
encapsulating a combination of gefitinib and vorinostat. 
 
Figure 2: Uptake of NP by A549 spheroids.  
A549 spheroid sections show membrane CD44 expression (in green), the specific binding 
of Dy-700-labeled NP (Dy-700 NP, in purple) after 24 hours, and their colocalization 
(merge). Nuclei are stained with Hoechst (in blue). Arrows show CD44 and NP 
colocalization in the same cells. Scale bars: 20 µm. 
 
Figure 3: Cell proliferation and apoptosis assays in NSCLC cells treated with DLNP. 
A549 cells in 2D monolayer cell culture were treated for 72 hours in absence of serum with 
vehicle (control), empty NP (Dy-700 NP), gefitinib/vorinostat-loaded NP (DLNP) or a 
combination of gefitinib and vorinostat at the same concentration as encapsulated in NP: 
185 µg/mL NP encapsulated gefitinib 15µmol/L/vorinostat 1.8µmol/L; 50 µg/mL NP 
encapsulated gefitinib 4µmol/L/vorinostat 0.5µmol/L. Cell viability (A) was determined at 
24, 48 and 72 hours. Results are expressed as the mean ± SD (representative experiment 
among 3). *p<0.05 compared to control; #p>0.05 as indicated. Caspase-3 activation (B) 
was detected by flow cytometry after 72 hours of treatment. Results are expressed as the 
mean ± SD (n≥2). *p<0.05 compared to control; #p>0.05 as indicated; ns not significant. 
 
Figure 4: Proliferation and apoptosis assays in NSCLC spheroids treated with DLNP. 
A549 spheroids were treated for 72 hours in absence of serum with vehicle (control), 
DLNP or a combination of gefitinib and vorinostat at the same concentration as 
encapsulated in NP: 185 µg/mL NP encapsulated gefitinib 15µmol/L/vorinostat 
1.8µmol/L; 50 µg/mL NP encapsulated gefitinib 4µmol/L/vorinostat 0.5µmol/L. A: The 
growth of spheroids is followed by microscopy at 24, 48 and 72 hours, and the volume is 
 30 
calculated using MetaMorph software. Data represent the mean ± SD of 20 spheroids in 2 
independent experiments. Representative images of A549 spheroids in each condition are 
presented. B: Cell viability was determined at 72 hours on spheroids. Data represent the 
mean ± SD of 20 spheroids in 2 independent experiments. C-F: A549 spheroids were 
treated in absence of serum (control), gefitinib/vorinostat-loaded NP (DLNP) or a 
combination of gefitinib and vorinostat at the same concentration as encapsulated in NP: 
50 µg/mL nanoparticles encapsulated gefitinib 4µmol/L/vorinostat 0.5µmol/L. 
Representative images of Ki67 (C) or cleaved-caspase 3 (E) staining detected through 
immunostaining on frozen spheroid sections are shown. In blue: Hoechst staining of the 
nuclei. Scale bar: 50 µm. Ki67 (D) or cleaved-caspase 3 (F) positive cells were quantified. 
Three slides randomly selected per spheroid were analyzed, counting all cells per slide. 
Histograms represent the mean ± SD of 3 spheroids. 
 
Figure 5: Biodistribution of NP and drugs after intravenous injection in vivo. 
In vivo biodistribution of Dy-700-labelled NP in mice with A549, H358, or H322 
subcutaneous tumors was studied. Fluorescence images were performed on isolated organs 
24 hours after intraveneous injection of NP. A: Regions of interest (ROI) are defined on 
the extracted organs to semi-quantify the amount of photons detected per pixel after a 500 
ms exposure. The results are expressed as the mean ± SD in A549 tumor-bearing mice 
(n=4), H358 tumor-bearing mice (n=2), and H322 tumor-bearing mice (n=4). The strongest 
fluorescence signals were measured in the liver and spleen. Examples of organs extracted 
from A549, H358, and H322 tumor-bearing mouse treated with Dy700-NP is presented. B: 
ROI are defined on the extracted tumors to semi-quantify the amount of photons detected 
per pixel after a 500 ms exposure after intravenous injection of NP. The results are 
expressed as the tumor/skin fluorescence ration ± SD in A549 tumor-bearing mice (n=4), 
H358 tumor-bearing mice (n=2), and H322 tumor-bearing mice (n=4). The NP fluorescent 
signal was 2 times higher in A549 tumors than in H322 or H358 tumors.  
 
Figure 6: Toxicity of NP and drugs after intravenous injection in vivo. 
Healthy mice were treated daily by intravenous injection of vehicle (control), Dy-700-NP 
(2 mg/mL), gefitinib/vorinostat-loaded nanoparticles (DLNP 2 mg/mL) or a combination 
of gefitinib and vorinostat at the same concentration as encapsulated in NP (gefitinib 72 
µg/mL and vorinostat 5.2 µg/mL). A: Mice were weighed each day. n=2-3 mice per 
condition. B: Gefitinib and vorinostat combination induced cutaneous rash. 
 
Figure 7: Effects of DLNP after nebulization in A549 orthotopic lung tumors. 
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Mice were inoculated with A549-Luc cells and randomized into 3 groups of 10 mice. 
Gefitinib/vorinostat-loaded NP (DLNP 2 mg/mL) or a combination of free gefitinib and 
vorinostat (gefitinib + vorinostat) at the same concentration as encapsulated in NP 
(gefitinib 72 µg/mL and vorinostat 5.2 µg/mL) were administered intrapulmonary in the 
lungs once a week. Thoracic bioluminescence imaging was performed once a week. A: 
Overtime bioluminescence images of A549-Luc tumors (one representative mouse per 
goup). B: DLNP inhibited the growth of orthotopic A549 lung tumors. Arrows shows 
treatment nebulization. Mice without signal or with bioluminescence only in the trachea 
have been excluded. Bars, SEM; control, n=6 mice; DLNP, n=8 mice; gefitinib + 
vorinostat, n=4 mice. Numbers indicate the percentage of lung tumor-bearing mice in each 
group. # This thoracic bioluminescent point has been estimated (dotted line) because of the 
failure of imaging in one mice. C-E: Tumor burden was measured at day 8 (C), day 15 
(D), and at the end of the experiment (day 42, E) and shown as a percentage of the control 
group. Numbers indicate the percentage of tumor growth inhibition compared to control 
group.  
 
Table 1: Serum biochemical values of healthy mice after NP or drugs administered by 
IV injection. 
Healthy mice were treated daily by intravenous injection of 1X PBS (control), Dy700-NP 
(2 mg/mL), gefitinib/vorinostat-loaded nanoparticles (DLNP 2 mg/mL) or a combination 
of gefitinib and vorinostat at the same concentration as encapsulated in NP (gefitinib 72 
µg/mL and vorinostat 5.2 µg/mL). After 11 days, blood was collected and analyzed using 
Dimension Vista® System according to manufacturer’s instructions. Data represented the 
means ± S.D. of 2-3 mice per condition. 
 
Table 2: Doubling time of tumor cell population and percentage of tumor-bearing 
mice after DLNP or free drug nebulization in mice with A549 orthotopic lung tumors. 
The tumor cell population doubling time was calculated as described in the methods 
section based on the longitudinal bioluminescence follow-up of mice with A549-Luc cells 
and nebulized with DLNP or gefitinib and vorinostat combination. The percentage of lung 
tumor-bearing mice in each group was determined at day 42 among the mice inoculated 
with A549-Luc cells (n=10 per group). 
Table 1: Serum biochemical values of healthy mice after NP or drugs administered by IV 
injection 
Serum biochemistry control Dy700-NP DLNP gefitinib + vorinostat 
reference 
values 
(range) 
Cl (mmol/L) 115.0 ± 2.1 112.3 ± 2.1 114.0 ± 0.8 115.4 ± 1.1 109-124 
K (mmol/L) 4.5 ± 1.5 4.8 ± 0.3 4.2 ± 0.1 3.5 ± 0.1 4-9 
Na (mmol/L) 149.9 ± 1.3 152.2 ± 2.5 153.3 ± 0.02 149.3 ± 0.6 147-167 
Ca (mmol/L) 2.4 ± 0.1 2.2 ± 0.03 2.4 ± 0.1 2.4 ± 0.1 2.25-3 
Creatinine (µmol/L) 14.1 ± 1.4 <12.5 <12.5 13.9 ± 1.1 5-60 
aspartate aminotransferase (U/L) 176.3 ± 193.8 226 ± 55.2 240.5 ± 10.6 66 ± 9.9 69-191 
alanine aminotransferase (U/L) 47.5 ± 26 24.9 ± 5.2 43.3 ± 0.8 33.8 ± 6.1 26-120 
total proteins (g/L) 48.6 ± 2.3 45.0 ± 0.1 50.0 ± 5.8 50.6 ± 1.9 47-55 
alkaline phosphatase (U/L) 110.3 ±33.3 57.0 ± 1.4 45.5 ± 2.2 144 ± 9.9 44-118 
Lipase (U/L) 117.0 ± 8.5 160.5 ± 14.8 168 ± 14.1 114.5 ± 14.8  
Healthy mice were treated daily by intravenous injection of 1X PBS (control), Dy700-NP (2 mg/mL), 
gefitinib/vorinostat-loaded nanoparticles (DLNP 2 mg/mL) or a combination of gefitinib and vorinostat at the same 
concentration as encapsulated in NP (gefitinib 72 µg/mL and vorinostat 5.2 µg/mL). After 11 days, blood was 
collected and analyzed using Dimension Vista® System and according to manufacturer’s instructions. Data 
represented the mean ± S.D. of 2-3 mice per condition. 
Table 1
Table 2: Doubling time of tumor cell population and percentage of tumor-bearing mice after 
DLNP or free drug nebulization in mice with A549 orthotopic lung tumors. 
  Doubling time of tumor cell population (days) 
Lung tumor-bearing mice 
(%) 
Control 17.1 ± 2.8 70 
DLNP 29.2 ± 5.5 80 
Gefitinib + vorinostat 13.3 ± 3.8 44 
The tumor cell population doubling time of was calculated as described in the methods section based on the 
longitudinal bioluminescence follow-up of mice with A549-Luc cells and nebulized with DLNP or gefitinib and 
vorinostat combination. The percentage of lung tumor-bearing mice in each group were determined at day 42 
among the mice inoculated with A549-Luc cells (n=10 per group).  
Table 2
Figure 1 
A 
B 
Dy-700 
C D 
0
2
4
6
8
10
12
14
16
18
20
0 10 20 30 40 50 60 70 80 90 100110120130
Re
le
as
e 
%
Time (h)
GEF
VOR
gefitinib 
vorinostat 
PDI = 0.22 
PDI = 0.16 
Figure 1
Figure 2 
CD44 Dy700-NP 
Hoechst merge 
Figure 2
* 
* 
* 
ns 
* 
# 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
Ap
op
to
si
s 
(%
) A549 2D 
Figure 3 
A 
B 
0 
50 
100 
150 
200 
250 
0 24 48 72 
Ce
ll 
pr
ol
ife
ra
tio
n 
(%
) 
hours of treatment 
A549 2D 
0 
50 
100 
150 
200 
250 
0 24 48 72 
C
el
l p
ro
lif
er
at
io
n 
(%
) 
hours of treatment 
A549 2D 
control 
Dy-700 NP 50µg/mL 
DLNP 50µg/mL 
gefitinib 4µM + vorinostat 0.5µM 
Dy-700 NP 185µg/mL 
DLNP 185µg/mL 
gefitinib 15µM + vorinostat 1.8µM 
* 
* 
* 
* 
* 
* 
# 
# 
* 
* 
* 
* 
Figure 3
Figure 4 
control Gef 4µM + vori 
0.5µM 
DLNP 50µg/mL 
A5
49
 s
ph
er
oi
ds
 Ki
67
 
Ho
ec
hs
t 
C D 
0 
1 
2 
3 
4 
5 
Control Gefitinib 4µM + 
vorinostat 0.5µM 
Loaded NP 
50µg/mL 
K
i6
7 
po
si
tiv
e 
ce
lls
 (%
) 
A549 spheroids 
control Gef 4µM + vori 
0.5µM 
DLNP 50µg/mL 
A5
49
 s
ph
er
oi
ds
 
Ac
tiv
e 
ca
sp
as
e-
3 
Ho
ec
hs
t 
E F 
0 
2 
4 
6 
8 
10 
Control Gefitinib 4µM + 
vorinostat 0.5µM 
Loaded NP 
50µg/mL 
%
 o
f a
po
pt
ot
ic
 c
el
ls
 
*** ** 
A549 spheroids 
DLNP 
DLNP 
A 
B 
0 
25 
50 
75 
100 
125 
0 24 48 72 Vo
lu
m
e 
of
 s
ph
er
oi
ds
 
(%
 o
f c
on
tro
l) 
Hours of treatment 
A549 spheroids 
control 
loaded NP 50µg/mL 
gefitinib 4µM + vorinostat 0.5µM 
loaded NP 185µg/mL 
gefitinib 15µM + vorinostat 1.8µM 
*** 
*** 
# 
*** 
*** *** 
DLNP 50µg/mL 
DLNP 185µg/mL 
ns 
0 
25 
50 
75 
100 
control loaded NP 
50µg/mL 
gefitinib 
4µM + 
vorinostat 
0.5µM 
loaded NP 
185µg/mL 
gefitinib 
15µM + 
vorinostat 
1.8µM 
Sp
he
ro
id
s 
vi
ab
ili
ty
 A549 spheroids 
# *** *** 
*** 
*** 
DLNP DLNP 
D
LN
P
 
18
5µ
g/
m
L 
T0            24h        48h           72h 
co
nt
ro
l 
D
LN
P
 
50
µg
/m
L 
ge
fit
in
ib
 4
µM
 +
 
vo
rin
os
ta
t 0
.5
µM
 
ge
fit
in
ib
 1
5µ
M
 +
 
vo
rin
os
ta
t 1
.8
µM
 
Figure 4
Figure 5 
A 
0 
10 
20 
30 
40 
50 
60 
he
ar
t 
lu
ng
 
br
ai
n 
sk
in
 
m
us
cl
e 
ki
dn
ey
 
ad
re
na
l g
la
nd
 
bl
ad
de
r 
in
te
st
in
e 
sp
le
en
 
pa
nc
re
as
 
fa
t 
st
om
ac
h 
ov
ar
y 
ut
er
us
 
liv
er
 
tu
m
or
 
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 
A549 
0 
10 
20 
30 
40 
50 
60 
he
ar
t 
lu
ng
 
br
ai
n 
sk
in
 
m
us
cl
e 
ki
dn
ey
 
ad
re
na
l g
la
nd
 
bl
ad
de
r 
in
te
st
in
e 
sp
le
en
 
pa
nc
re
as
 
fa
t 
st
om
ac
h 
ov
ar
y 
ut
er
us
 
liv
er
 
tu
m
or
 
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 
H358 
0 
10 
20 
30 
40 
50 
60 
he
ar
t 
lu
ng
 
br
ai
n 
sk
in
 
m
us
cl
e 
ki
dn
ey
 
ad
re
na
l g
la
nd
 
bl
ad
de
r 
in
te
st
in
e 
sp
le
en
 
pa
nc
re
as
 
fa
t 
st
om
ac
h 
ov
ar
y 
ut
er
us
 
liv
er
 
tu
m
or
 
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 
H322 
Heart Lung Brain Skin 
Muscle kidney Adrenal Bladder 
Gut Spleen Pancreas Fat 
Stomach Uterus Liver Tumor 
A549 
2D ex vivo fluorescence (24h) 
B 
0 
0.5 
1 
1.5 
2 
2.5 
3 
ratio tumeur / peau 
Tu
m
or
/s
ki
n 
 fl
uo
re
sc
en
ce
 ra
tio
 
H322 
H358 
A549 
Heart Lung Brain Skin 
Muscle kidney Adrenal Bladder 
Gut Spleen Pancreas Fat 
Stomach Uterus Liver Tumor 
H322 
2D ex vivo fluorescence (24h) 
Heart Lung Brain Skin 
Muscle kidney Adrenal Bladder 
Gut Spleen Pancreas Fat 
Stomach Uterus Liver Tumor 
H358 
2D ex vivo fluorescence (24h) 
Figure 5
control DLNP 
Gefitinib + 
vorinostat 
rash 
B 
Figure 6 
0 
5 
10 
15 
20 
25 
30 
0 1 2 3 4 5 6 7 8 9 10 11 12 
W
ei
gh
t o
f m
ic
e 
(g
) 
Days of treatment 
control 
Dy700-NP (2mg/mL) 
Loaded-NP (gef 72µg/mL + vori 5.2µg/mL) 
gefitinib 72µg/mL +vorinostat 5.2µg/mL 
IV injection 
DLNP 
A 
Figure 6
5.104  
1.106 Co
nt
ro
l 
Ge
fit
in
ib
 + 
vo
rin
os
ta
t 
DL
NP
 
D8 D15 D22 D29 D36 D42 
Figure 7 
A 
B 
C D E 
0.00E+00 
1.00E+07 
2.00E+07 
3.00E+07 
4.00E+07 
5.00E+07 
0 5 10 15 20 25 30 35 40 
Th
or
ac
ic
 b
io
lu
m
in
es
ce
nc
e 
 
(p
ho
to
ns
/s
ec
) 
Days 
Control 
Loaded-NP 
gefitinib + vorinostat 
estimation of gefitinib + vorinostat 1.00E+08 
5.00E+08 
9.00E+08 
# 
DLNP 
0 
25 
50 
75 
100 
125 
150 
Tu
m
or
 b
ur
de
n 
(%
 o
f c
on
tro
l) 
-52% 
-65% 
Day 8 
0 
25 
50 
75 
100 
125 
150 
Tu
m
or
 b
ur
de
n 
(%
 o
f c
on
tro
l) 
-44% 
-72% 
Day 15 
0 
25 
50 
75 
100 
125 
150 
Tu
m
or
 b
ur
de
n 
(%
 o
f c
on
tro
l) 
-31% 
-82% 
Day 42 
Figure 7
